Zobrazeno 51 - 60
of 1 168
pro vyhledávání: ''
Autor:
Cristina Saura, Mafalda Oliveira, Valentina Gambardella, Kevin Kalinsky, Andrés Cervantes, Naoki Kotani, Ian E. Krop, Zachary William Neil Veitch, Komal Jhaveri, Dejan Juric, Erika Hamilton, Antoine Italiano, Anjali Vaze, Stephanie Royer-Joo, Katie Hutchinson, Peter Schmid, Philippe L. Bedard, Jennifer L. Schutzman, Nicholas C. Turner, Andrea Varga, Amy V. Kapp, Leslie J. Dickmann
Publikováno v:
Cancer Research. 80:P1-19
Background: Dysregulation of the PI3K/AKT/mTOR signaling pathway occurs in solid tumor malignancies. GDC-0077 (G) is a potent p110α-selective, p110α-mutant degrading inhibitor with anti-tumor activity in PIK3CA-mutant breast cancer xenograft models
Autor:
Nuhad K. Ibrahim, Mark D. Pegram, Anita Fung, Anna Cheng, Bei Wang, Priya Kumthekar, Solmaz Sahebjam, Alan Nicholas, Nan Lin
Publikováno v:
Cancer Research. 80:P1-18
Background: There is an unmet need for evidence-based systemic therapies for pts with HER2-positive MBC and progressive brain metastases. Despite assumptions that monoclonal antibodies do not cross the blood-brain barrier, molecular imaging in pts sh
Autor:
Eustratios Bananis, Sherene Loi, Eric Gauthier, Massimo Cristofanilli, Richard S. Finn, Kathy Puyana Theall, Hope S. Rugo, A. Mori, Dongrui R. Lu, Nicholas C. Turner, Patrick Schnell, Karen A. Gelmon, Marco Colleoni, Véronique Diéras
Publikováno v:
Cancer Research. 80:P1-19
Background Palbociclib (PAL) in combination with endocrine therapy (ET) was shown to be tolerable in a previous pooled analysis of the 3 PALOMA clinical trials. This new pooled, post hoc analysis examines the safety profile of PAL + ET using data fro
Autor:
Charles E. Geyer, Chiun-Sheng Huang, Lisa H. Lam, Gunter von Minckwitz, D. Tesarowski, Sibylle Loibl, Norman Wolmark, Chunyan Song, Youngsen Yang, Sherko Kümmel, Irene Wapnir, Martina Zimovjanova, Max S. Mano, Haying Liu, Claudia Strunk, Alison Conlin, Steven Blotner, Michael P. DiGiovanna, Mahasti Saghatchian, Melanie Smitt, Michael Untch, Eleftherios P. Mamounas
Publikováno v:
Cancer Research. 80:P3-14
Background: Patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy (NACT) + HER2-targeted therapy have a higher risk of recurrence and death than those with pathologic complete response. In the p
Autor:
Lorenzo Trippa, Ann H. Partridge, Beth Overmoyer, Karla Helvie, Eric P. Winer, Chelsea Andrews, Sara M. Tolaney, Romualdo Barroso-Sousa, Arlindo R Ferreira, Nikhil Wagle, Rebecca Rees, Tianyu Li
Publikováno v:
Cancer Research. 80:P5-11
Background: For patients (pts) with HR+ /HER2- MBC, the optimal regimen following disease progression on the combination of a CDK4/6i plus endocrine therapy (ET) is unknown, and there is a need to evaluate whether continued CDK 4/6 blockade is benefi
Autor:
Matthew C Winter, Daniel Rea, Peter Stephens, Rebecca Roylance, Nicholas C. Turner, Jeremy P Braybrooke, Hannah Bye, Lucy Kilburn, Claire Snowdon, Sarah Kernaghan, Iain R. Macpherson, Judith M Bliss, Richard D. Baird, Mike Hubank, Abeer M Shaaban, Andrew M Wardley, Katie Wilkinson, Alistair Ring, Mark Tuthill, Jacinta Abraham, Katrina Randle, Belinda Kingston, David Cameron, Olga Oikonomidou, Laura Moretti
Publikováno v:
Cancer Research. 80:GS3-06
Background: Circulating tumour DNA (ctDNA) testing may provide a more current assessment of the genetic profile of advanced breast cancer (BC) compared with analysis of the primary tumour, with repeat advanced disease biopsy conducted infrequently in
Autor:
Whitney P. Kirschbrown, Daniil Stroyakovskii, Christian Jackisch, Christian Schem, Tanja Badovinac Crnjevic, Antoinette R. Tan, Zbigniew Nowecki, Michelino De Laurentiis, Kyung Hae Jung, Mahesh Shivhare, André Mattar, Seock-Ah Im, Sarah Heeson, Eleonora Restuccia, Ramon Colomer, Jean-Yves Pierga
Publikováno v:
Cancer Research. 80:PD4-07
Background: Intravenous pertuzumab (P IV) + trastuzumab (H IV) + chemotherapy (CT) improves outcomes in patients (pts) with HER2-positive breast cancer, compared with H + CT.A new subcutaneous (SC) formulation, for the first time combining two monocl
Publikováno v:
Cancer Research. 80:OT1-07
Background: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have greatly improved survival in subjects with HER2-positive breast cancer (BC). However, there are many more subjects with BC with HER2-low expression (immunohistochemis
Publikováno v:
Cancer Research. 80:P1-19
Background: Ribociclib (RIB) is an oral CDK4/6 inhibitor used in combination with endocrine therapy (ET) to treat women with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative locally advanced breast cancer (ABC). ET p
Autor:
Maritza Martel, Walter J. Urba, Zhaoyu Sun, Shu-Ching Chang, Joanna Pucilowska, William L. Redmond, Brady Bernard, Isaac Yi Kim, Katherine Sanchez, David B. Page, Yaping Wu, Dottie Waddell
Publikováno v:
Cancer Research. 80:P6-10
Introduction: Anti-PD-1/L1 (atezolizumab) is effective in first-line, PD-L1-positive triple negative breast cancer, however it is becoming increasingly apparent that the majority of breast cancers will require novel I-O combination strategies. We des